DiaDexus Receives FDA Clearance for PLAC Activity Test

DiaDexus Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PLAC Test for Lp-PLA₂ Activity.

This new test is an enzyme assay for the quantitative determination of Lp-PLA₂ (Lipoprotein-Associated Phospholipase A₂) activity in human plasma and serum. An analysis based on REGARDS, a U.S.-based National Institutes of Health-funded longitudinal study, using a cohort of approximately 4,500 individuals with no prior history of cardiovascular events, demonstrated that elevated Lp-PLA₂ Activity levels are associated with a significant increase for risk of coronary heart disease.

“The FDA’s clearance of our second test is an important step in achieving our vision of evolving from a single-product business into a multi-product company,” said Lori Rafield, Ph.D., interim executive chair and diaDexus board chairman. “This new PLAC Activity test has demonstrated robust analytical performance and can be used broadly by moderate-complexity reference labs, hospital labs, and physician office labs using a wide range of typical clinical chemistry analyzers, allowing us to meaningfully expand our customer base.”

The first indication for the new test is for use in conjunction with clinical evaluation and patient risk assessment to help predict coronary heart disease (CHD) risk in patients with no prior history of cardiovascular events, which is approximately 75 percent of this population. According to the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, more than 16 million Americans are at moderate risk for a first atherosclerotic cardiovascular disease event over the next decade.

Evidence supporting the clinical utility of PLAC Activity was based on data from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study as well as peer-reviewed literature supporting Lp-PLA₂ as an important cardiovascular risk marker.

Cardiovascular disease (CVD), which results in heart attacks, strokes and other cardiovascular events, represents the leading cause of death and disability in the United States. As many as 85 million Americans have an elevated risk of CVD, and in total, cardiovascular-related events cost the U.S. healthcare system an estimated $400 billion each year. Although it is common knowledge that high cholesterol is a significant risk factor for CVD, cholesterol testing alone is often not enough to identify patient at risk for CVD. Fifty percent of hearts attacks occur in patients with normal cholesterol levels, with the majority of heart attacks and ischemic strokes caused by plaque rupture, in which vascular inflammation plays a key role. For thirty percent of patients, sudden cardiac death is the first symptom of heart disease.

Lipoprotein-Associated Phospholipase A₂ is a vascular-specific inflammatory marker that is critical in the formation of rupture-prone plaque. When elevated, this enzyme indicates arterial inflammation, which is associated with increased risk for heart attack and stroke. The higher the level of Lp-PLA₂, the higher the risk of a cardiovascular event, even when LDL is normal.

PLAC Tests are simple blood tests that measure Lp-PLA₂ levels in a patient’s blood. diaDexus has developed and commercialized two FDA-cleared PLAC Tests. The PLAC Test ELISA Kit is an aid in predicting risk for CHD and ischemic stroke associated with atherosclerosis and is commercially available in the United States. The PLAC Test for Lp-PLA₂ Activity is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of CHD in patients with no prior history of cardiovascular events.

Based in San Francisco, Calif., DiaDexus develops and commercializes proprietary cardiovascular diagnostic products. The company claims its Plac Test Elisa Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis.